Articles tagged with Drug Development
The ISSCR 2026 Annual Meeting will bring together academic and industry leaders to explore advances in stem cell science and regenerative medicine. Scientists can submit abstracts by February 25, 2026, for oral presentations and Travel and Merit Awards.
The Critical Path Institute has been recognized for its innovative approaches to regulatory science, which have measurably improved public health. The organization's work in creating practical tools and cross-sector collaborations has shortened drug development timelines and improved regulatory decisions.
Denis Evseenko and Toby Maher are developing a regenerative drug to block cells that promote fibrosis in the lungs, aiming to slow or reverse IPF damage. The team plans to test the safety and therapeutic potential of their drug-like molecules in animals and human cells.
Isha Jain wins NIH Transformative Research Award to develop new targeted treatments using modern science and techniques, potentially leading to personalized vitamin-based therapies for genetic disorders. Her lab has made key discoveries on oxygen levels and tissue damage, aiming to fine-tune these processes for disease treatment.
A new study reveals that stevioside can effectively promote hair follicles to enter the growth phase when combined with minoxidil. The natural sweetener enhances skin absorption of the drug, leading to new hair development in a mouse model of alopecia.
A University of Houston professor has received funding to develop effective treatments for Cryptosporidium infections, which cause severe diarrhea and have no existing cure. The team aims to design drugs that target the parasite's enzyme CDPK1 to minimize systemic exposure and maximize efficacy.
A new MOF, APF-80, enables the crystalline sponge method to capture and analyze nucleophilic compounds like alkaloids. This development opens possibilities for structural analysis in drug development and biochemistry.
A new survey found that 72% of respondents agree that plasma-derived medicines can save lives, but most haven't donated. Plasma is essential in producing treatments for various serious health conditions.
A historic campaign in Argentina developed antivenom for black widow spider bites, leading to a model for pharmaceutical autonomy. This approach is crucial for fighting neglected tropical diseases globally.
Researchers at the University of Bath develop a peptide fragment that locks alpha-synuclein into its healthy shape, blocking toxic clumps that cause nerve cell death. The breakthrough demonstrates the potential of rational peptide design to transform large proteins into compact drug-like molecules.
Scientists successfully derive and maintain self-renewing and pluripotent ESCs from chickens and seven other bird species using a growing medium of egg yolk. The study holds promise for applications in studying embryonic development, producing lab-grown poultry, and reviving endangered birds.
A new study finds that over 50% of small-molecule drug patents this century are connected to NIH-backed research that would likely be cut under a 40% budget reduction. This highlights the significant impact of federally funded research on the development of life-changing medicines.
A large international clinical trial found that elinzanetant significantly reduces hot flashes and night sweats in postmenopausal women by over 73%. The drug also shows secondary benefits such as improved quality of life and reduced sleep disturbances, with no harmful effects on the liver or bone density.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
Researchers at the University of Maine Forest Bioproducts Research Institute have discovered a sustainable method to produce (S)-3-hydroxy-γ-butyrolactone, a crucial building block in pharmaceuticals. This approach could significantly reduce greenhouse gas emissions and production costs by up to 60%.
A new white paper from the USC Schaeffer Center recommends FDA reforms to streamline clinical trials, provide clearer guidance on newer technologies, and improve agency efficiency. This could reduce development time and costs, pushing down prices and improving patient access.
A new study from Mizzou's College of Veterinary Medicine analyzed the effects of radioactive iodine therapy on thyroid cancer in dogs. The research found that tailoring the dose of radiation more precisely for each dog could improve outcomes and potentially lead to more targeted care.
A novel drug target, CD300a, has been identified to suppress immune cell activation and prevent chronic heart and kidney failure after acute tissue injury. The treatment preserves cardiac function and reduces renal fibrosis in mice with genetic deficiency of CD300a.
The C-Path Translational Therapeutics Accelerator has completed a record year of funding and mentorship, supporting seven projects in 2025 with approximately $2.48 million in awards. The program awarded grants to teams advancing treatments for rare liver disease, drug-resistant lung infections and pediatric brain tumors.
Ibezapolstat, a new antibiotic, has been shown to be effective in treating Clostridioides difficile (C. diff) infections with high rates of sustained clinical cures. The study found that ibezapolstat killed harmful bacteria without harming the good bacteria in the gut, which helps prevent recurrent C. diff infections.
Researchers propose idiopathic pulmonary fibrosis as a disease-specific treatment to test general geroprotector therapies, leveraging its high overlap with aging biology. This approach could accelerate drug development and reduce costs by targeting shared biological pathways.
USC Stem Cell scientists have developed a blueprint for generating specific kidney cell types on demand, holding immense value for preclinical studies of new therapeutics and congenital kidney diseases. The team successfully created lab-grown proximal tubule cells that can absorb sugar and protein, respond to chemotherapy drugs, and pr...
Researchers have identified a new class of compounds derived from psychedelics that could open the door to safe, targeted therapies for widespread use in clinical settings. These PIPI drugs may modulate the immune system to control inflammation, potentially treating conditions such as Alzheimer's and Parkinson's disease.
A synthetic molecule called Pep19 has been shown to reduce visceral fat and improve sleep quality in overweight adults, with no side effects observed. The study involved 24 volunteers who took either a placebo or Pep19 in capsules, and found a 17% reduction in visceral fat and improved sleep quality in those who received the molecule.
Scientists at CUNY ASRC develop novel synthetic carbohydrate receptors that block infection from seven different viruses across five unrelated families, including Ebola and SARS-CoV-2. The breakthrough offers a promising path toward the development of broad-spectrum antivirals.
A new study offers a powerful AI-assisted method for uncovering exactly how TB drugs kill the bacteria, which could lead to smarter treatment combinations. The approach uncovers molecular details of drug interactions and can predict their impact from images alone.
Researchers found that a faster rate of binding does not always translate to greater potency, as the study's lead author David Heppner explained. The team proposed a two-step design process balancing inactivation efficiency rates with target selectivity and other parameters to identify promising compounds.
Climate-related disasters pose significant disruptions to US drug manufacturing facilities, affecting nearly two-thirds of production sites. Researchers assessed the impact of disaster events on counties with US drug production facilities and found that nearly two-thirds were located in areas affected by at least one disaster declaration.
The new model can predict how well any given molecule will dissolve in an organic solvent, helping chemists choose the right solvent for reactions. The researchers trained two models on a comprehensive dataset and found that their predictions were two to three times more accurate than the previous best model.
MIT researchers have developed a method to reveal the inner workings of protein language models, which can accurately predict proteins suitable for drug or vaccine targets. By analyzing sparse representations of proteins, they identified key features that drive these predictions.
Researchers develop novel treatment for acetaminophen-induced liver injury (AILI) using a GSDMD inhibitor. YM81 selectively binds to and inhibits the pyroptosis protein gasdermin D, reducing liver inflammation and damage.
Researchers designed over 36 million compounds using generative AI algorithms and computationally screened them for antimicrobial properties. The top candidates show promise against Neisseria gonorrhoeae and Staphylococcus aureus (MRSA) by novel mechanisms that disrupt bacterial cell membranes.
A study in mice found that high triglyceride levels directly cause abdominal aortic aneurysms, challenging the notion that they are merely biomarkers of vascular disease. Researchers identified specific proteins and lipoproteins as causal drivers of aneurysm development and growth.
Researchers trained GAMES to generate accurate SMILES combinations, enhancing computer-aided drug design and accelerating discovery. The model combines LoRA and QLoRA techniques to reduce hardware and energy needed.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
The new handbook provides a practical approach to harnessing zebrafish as a model organism for biomedical research, covering drug efficacy evaluation and disease mechanisms. It offers step-by-step experimental protocols and theoretical grounding for researchers of all levels.
Researchers developed a neoAg mRNA-based vaccine that induces higher frequency of neoAg-specific cytotoxic T cells in mice, leading to tumor regression and eradication. The combination with anti-PD-1 therapy enhances antitumor efficacy, especially against peritoneal metastasis.
Researchers at the University of Pennsylvania used AI to identify previously unknown compounds in Archaea that could fuel the development of next-generation antibiotics. The study, published in Nature Microbiology, found that 93% of the identified archaeasins demonstrated antimicrobial activity against drug-resistant bacteria.
The new book explores organoid bioengineering, using pluripotent and adult stem cells to create models for various organs. It discusses breakthroughs in personalized cancer care and large-scale production protocols supported by advanced tools like 3D printing and genome editing.
Researchers have found a way to rearrange atoms in a new generation of malaria drugs to make them more soluble, maintaining their effectiveness against drug-resistant parasites. This breakthrough could lead to an effective successor to artemisinin-based combination therapy.
Researchers find large language models (LLMs) can predict drug-target interactions more accurately. LLMs are advancing drug discovery by optimizing molecule design and improving model reliability.
MIT researchers developed a fully autonomous experimental platform that can efficiently identify optimal polymer blends. The system uses a genetic algorithm to explore a wide range of potential combinations and autonomously identifies hundreds of blends that outperform their constituent polymers. This workflow could lead to advancement...
Researchers at the University of Arkansas have created a new controlled release system that uses cellulose nanocrystals and alginate to deliver bioactive compounds to specific areas of the body. The system protects medications from acid in the stomach and releases them in alkaline environments, such as the intestines.
A new treatment for corneal scarring is being developed by University of Houston optometry researcher Tarsis G. Ferreira. The treatment uses a natural protein called decorin to block scarring and unwanted blood vessel growth, offering hope for people with injured corneas.
A study from Gladstone Institutes reveals that genetic risk factors for neurological diseases like Alzheimer’s and stroke exert their effects in blood vessels and immune cells. The research provides a detailed look at how genetic variants function across all major brain cell types, revealing distinct mechanisms for different diseases.
UCSF scientists identified a receptor that enables microglia to engulf and digest amyloid beta plaques, leading to fewer and smaller clumps. This discovery creates an opportunity for new therapies targeting the receptor ADGRG1.
The European Research Council has awarded three ERC Proof of Concept grants to Göttingen University professors, enabling the development of initiatives that can benefit Europe's economy and society. The projects focus on harnessing renewable energy, reducing chemical waste, and improving biomedical image analysis.
A potent new dual lipid kinase inhibitor, RMC-113, selectively inhibits PIKfyve and PIP4K2C, providing a potential strategy to combat emerging viruses. The study reveals that PIP4K2C plays a crucial role in SARS-CoV-2 entry, replication, and assembly/egress, making it an understudied kinase with significant antiviral potential.
Clinical trials show that sutezolid and delpazolid are safer alternatives to linezolid, with strong antimicrobial activity and fewer side effects. These novel antibiotics have the potential to replace linezolid in TB treatment regimens, particularly for long-term use.
Scientists from the University of Bath have identified two new families of chemical compounds that inhibit alpha-methylacyl-CoA racemase (MCR) in Mycobacterium tuberculosis, a key enzyme for TB survival. This breakthrough could lead to new treatments for TB and potentially other diseases like prostate cancer.
Researchers at Fujita Health University discovered benzaldehyde's mechanism to halt therapy-resistant pancreatic cancer growth and spread. Benzaldehyde prevents key interactions that enable cancer cells' survival and treatment resistance.
Researchers found that hyperactivation of the PARP1 protein after exhaustive training is associated with decreased performance, fatigue, and behavioral symptoms of overtraining. A study published in Molecular Metabolism suggests that excessive protein expression may be the cause of the syndrome.
Scientists have developed a method to produce macrocyclic peptides using brewer's yeast, which can be rapidly analyzed for therapeutic applications. The approach harnesses the natural machinery of yeast to create biocompatible and biodegradable peptide molecules with precision targeting and stability.
A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.
A new approach enables hospital pharmacists to rapidly create bespoke medicine cartridges for rare disease patients, boosting access to personalized treatment. The NANOSPRESSO platform could open up treatments for underfunded and underserved rare conditions worldwide.
Lars Lannfelt's pioneering research on Alzheimer's disease led to the development of lecanemab, a first-ever disease-modifying drug in EU. The €60,000 Hartwig Piepenbrock-DZNE Prize honors his contributions to understanding Alzheimer's and slowing its progression.
UVA Health received two anonymous $25 million estate gifts to support the Paul and Diane Manning Institute of Biotechnology. The institute will develop new treatments for hard-to-treat diseases with a state-of-the-art biomedical research facility expected to drive economic growth in Central Virginia.
A new Center for Protein Design at the University of Copenhagen aims to create artificially designed proteins with tailored properties to tackle diseases, environmental issues, and industrial applications. The centre will drive fundamental research and translate basic findings into concrete solutions.
A phase 3 trial demonstrated the efficacy of selumetinib in reducing tumor size and alleviating pain in adults with neurofibromatosis type 1. The treatment was found to be effective in patients who received it from day one, as well as those who started it later, with significant reductions in tumor size and pain reported.